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Norcantharidin induces G2/M arrest and apoptosis via activation 
of ERK and JNK, but not p38 signaling in human renal cell 
carcinoma ACHN cells
Renal cell carcinoma (RCC) is generally acknowledged as 
the most resistant primary malignancy unresponsive to 
conventional radiotherapy and chemotherapy treatments. 
Norcantharidin (NCTD), a therapeutic compound derived 
from medicinal plants, has been shown to trigger apoptosis, 
as well as antimetastatic and antioxidant activities in  several 
tumor cells. However, NCTD’s mechanism of antitumor 
activity in the RCC cell line remains unclear. In this study, 
we report that NCTD led to a time- and dose-dependent 
inhibition of cell proliferation. It had also markedly induced 
apoptosis and G2/M phase cell cycle arrest in a dose-depen-
dent manner by decreasing the expressions of pro-caspase-3, 
pro-caspase-9, cyclin B1, and pCDC25C while increasing 
active caspase-3, cleaved-PARP, P21, and pCDC2 levels. 
 Interestingly, NCTD treatment provoked the phosphoryla-
tion of extracellular-regulated protein kinase (ERK) and 
 c-Jun-N-terminal kinase (JNK), but not of p38 MAPK. More-
over, SCH772984 and SP600125, ERK and JNK inhibitors, 
respectively, could partially abolish NCTD-induced apoptosis 
and G2/M phase cell cycle arrest. Collectively, these findings 
suggest that NCTD might activate JNK and ERK signaling 
pathways, consequently inducing apoptosis and G2/M  arrest 
through the modulation of related proteins. This study 
 provided evidence that NCTD is a promising therapeutic 
drug for the treatment of RCC.
Keywords: norcantharidin, renal cancer cells, ERK, JNK, p38 
MAPK, apoptosis, cell cycle arrest
Renal cell carcinoma (RCC) is the most commonly occurring malignancy in kidneys, 
specifically in the proximal renal tubular epithelial cells (1). Due to frequent metastasis, 
only one-third of RCCs can be effectively managed by resection, chemotherapy and radio-
therapy (2, 3). Hence, new molecular targets should be identified, and more effective and 
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Cantharidin is a traditional Chinese medicine extracted from the dried body of blister 
beetle (Mylabris phalerata, Pallas) known for its antitumor properties. Its properties can be 
traced back to 2000 years ago since it has been used for a long time. However, it causes side 
effects like leukocytosis and the stimulation of the urinary system (4–6).
For the sake of finding a cantharidin analogue with fewer side effects, norcantharidin 
(NCTD), a demethylated form of cantharidin, was prepared. NCTD exhibited stronger 
antitumor activity and caused fewer metabolic disturbances and nephrotoxicity than can-
tharidin because it could prevent hydroperoxide production in macrophages, and main-
tain tissue homeostasis in the kidney (7–9). Furthermore, NCTD inhibited the proliferation 
of metastatic, angiogenic, antioxidant, and antitubulointerstitial fibrosis, and also induced 
apoptosis and cell cycle arrest (10–13). The antitumor activity of NCTD has been observed 
in various types of cancer cells, such as prostate, breast, melanoma, and hepatocellular 
carcinomas (13–16). Nevertheless, only a few reports exist in the literature regarding the 
cytotoxic effects of NCTD on RCC cells.
Certain anticancer chemotherapeutic drugs exert their antitumor activities via the 
induction of cell cycle arrest and apoptosis (17). During the transition, a series of cyclins 
and cyclin-dependent kinases (CDKs) accurately regulate the progression of the cell cycle. 
Therefore, the abnormal expression of such proteins may lead to cell cycle arrest or cell 
death (18, 19). In addition to blocking cell cycle progression, chemotherapeutic drugs often 
cause apoptosis, a process of programmed cell death that occurs in response to toxicants 
(20, 21). Several biomarkers, such as Bcl-2 family and caspase family proteins, could be 
regarded as the determinants of apoptosis (22–24). Among these biomarkers, caspase-9 is 
responsible for activating other caspase members, while caspase-3 acts as the final apop-
totic executive molecule (25, 26).
Mitogen-activated protein kinases (MAPKs) play an important role in the process of 
intracellular signal transduction by managing cellular responses to a diverse array of 
stimuli that regulate cell functions, including cell proliferation, differentiation, mitosis 
and apoptosis (27, 28). Extracellular-regulated protein kinase (ERK), c-Jun-N-terminal kinase 
(JNK), and p38 MAPK are key members of the MAPK family that are associated with the 
induction of cell cycle arrest and apoptosis (28, 29). However, it is unclear whether the 
MAPK signaling pathway participates in NCTD-induced cell apoptosis.
In this study, we observed the antitumor activity of NCTD with respect to RCC cells. 




A 100 mmol L–1 standard NCTD solution (≥ 98 %) was prepared by dissolving NCTD 
powder, purchased from Solarbio (Beijing, China), in dimethylsulfoxide (DMSO), and it 
was stored at 4 °C. Working solutions were freshly prepared from the standard solution 
and used in cell culture media. Fetal bovine serum (FBS), penicillin, streptomycin, and 
MTT were obtained from Sigma-Aldrich (USA).
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Cell cultures
The ACHN human renal carcinoma cell lines were purchased from the Cell Bank of 
the Chinese Academy of Sciences (China). ACHN cells were cultured in DMEM (Hyclone, 
USA). All cells were incubated at 37 °C in 5 % CO2 after supplementing the culture media 
with 10 % heat-inactivated fetal bovine serum (Hyclone, NZ), 100 U mL–1 streptomycin, 
and 100 mg mL–1 penicillin (Hyclone, USA).
MTT assays
Cell toxicity experiments were performed using the CellTiter96® AQueous One Solu-
tion Cell Proliferation Assay (Promega, Madison, Wisconsin, USA) according to the manu-
facturer’s protocol. Briefly, cells were plated in 96-well plates at a density of 2000 cells/well. 
20 μL of CellTiter 96® Aqueous One Solution Reagent were added to each well after cultur-
ing for 24, 48, 72, and 96 h at 37 °C. Absorbance values were measured at 492 nm using a 
spectrophotometer.
Flow cytometric analysis
The cell cycle detection kit (MultiSciences, China) and the AnnexinV/propidium iodide 
(PI) apoptosis detection kit (MultiSciences) were used to determine the effect of NCTD on 
cell cycle distribution and the percentage of apoptotic cells. For cell cycle analyses, ACHN 
cells were cultured in 6-well plates then trypsinized and fixed in 100 % ethanol at –20 °C 
for 24 h. The cell pellets were then stained with PI and simultaneously treated with RNase 
for 30 min at room temperature before being analyzed using a BD FACScan laser flow 
cytometer. The obtained data were analyzed using MODFIT and CellQuest software. 
Meanwhile, for cell apoptosis analysis, 1.0 × 106 cells were harvested and washed with cold 
PBS then resuspended in 1.0 mL binding buffer containing 5 μL Annexin V-FITC and 1 μL 
PI. These cells were detected immediately after supravital staining. Cells distributed in 
Annexin V positive and PI negative stand for the early stage of apoptosis, and late stages 
of apoptosis were both Annexin V and PI positive (30).
Western blot analysis
For Western blot analyses, cells were lysed with RIPA buffer (Solarbio, China) contain-
ing 1 % PMSF protease inhibitor (Solarbio). Total protein concentrations were measured 
using the BCA protein assay kit (Beyotime, China). Total protein (35 μg) samples were 
loaded and separated using 12 % SDS-PAGE, transferred to PVDF membranes, blocked 
with 5 % non-fat dry milk, and then incubated overnight with specific primary antibodies 
(Supplementary Material 1) at 4 °C. Thereafter, the blots were washed with TBST, incubated 
with horseradish peroxidase-labeled secondary antibodies (Boster, China), and visualized 
using an enhanced chemiluminescence reagent (Clinx, China). The gray value of each blot 
was detected by a gel imaging system (Tanon, China).
Inhibitor treatment
To investigate the effect of MAPK inhibitors on NCTD-induced apoptosis and cell 
cycle arrest, cells were pretreated for 1 h with 1 μmol L–1 SCH772984 (ERK specific Inhibi-
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tor) (Selleckchem, USA) or 5 μmol L–1 SP600125 (JNK specific inhibitor) (Selleckchem) or 5 
μmol L–1 SB203580 (p38 MAPK specific inhibitor) (Selleckchem) before the addition of 
NCTD.
Statistical analysis
All data were shown as means ± SD of three independent experiments. Data were 
analyzed using SPSS software, version 18.0 (SPSS, Inc., USA). Statistically significant dif-
ferences between the two groups were determined by Student’s t-test, three or more than 
three groups were calculated using ANOVA (post hoc test: Dunnett’s, multiple compari-
sons), p < 0.05 was considered as statistically significant.
RESULTS AND DISCUSSION
Effective antitumor drugs are urgently needed to improve the prognosis of renal can-
cer. Recently, it has been reported that NCTD, a highly cytotoxic compound, is a promising 
anticancer drug, particularly considering fewer side effects and stronger antitumor acti-
vities associated with its use (8, 9). The aim of this study is to investigate the effect of NCTD 
on RCC cells and elucidate the underlying mechanisms.
Several studies have proven that NCTD constrains the proliferation of various types 
of tumor cells (8, 13–15). The structure of NCTD is presented in Fig. 1a. To explore the role 
of NCTD in cell growth, ACHN cells were treated with NCTD solutions at concentrations 
of 0, 10, 50, 100, 500, or 800 μmol L–1 for 0, 24, 48, 72, or 96 h. MTT assay results showed that 
NCTD substantially inhibits ACHN cell growth in a time- and dose-dependent manner 
(Fig. 1b). The concentration resulting in 50 % inhibition of NCTD after 24, 48, 72 and 96 h 
treatment was shown in Table 1. In our preliminary experiment, we discovered that a low 
concentration of NCTD (10 μmol L–1) could modify the cell cycle and early apoptosis, but 
it didn’t significantly inhibit cell proliferation. Therefore, the concentrations of 10, 100 and 
200 μmol L–1 were applied for further experiments. Exposure of ACHN cells to NCTD for 
24 h induces G2/M phase cell cycle arrest (Fig. 2a). This effect becomes more prominent as 
the concentration of NCTD increases between 0 and 200 μmol L–1. Generally, cell cycle 
Fig. 1. NCTD inhibited cell proliferation in ACHN cells. a) Chemical structure of NCTD, b) cell pro-
liferation of ACHN measured by MTT assay.
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Fig. 2. NCTD induced G2/M phase cell cycle arrest and altered cell cycle-regulatory proteins expres-
sions in ACHN cells. a) Cell cycle distribution and b) related regulatory proteins monitored after treated 
with 0, 10, 100, and 200 μmol L–1 NCTD for 24 h. *p < 0.05, **p < 0.01, ***p < 0.001 vs. control group.
a)
b)
transmission requires the coordination of several key proteins. Both cyclin B1 expression 
and dephosphorylation of pCDC2 are needed to activate the CDC2/cylcin B1 complex and 
cross the G2/M checkpoint to enter mitosis (31, 32). The CDC2/cylcin B1 complex may be 
repressed by P21; thus, the accumulation of P21 in the nuclei near the G2/M boundary 
could result in the G2/M phase block (33). Meanwhile, the translocation of CDC25C protein 
phosphatase into cellular nuclei catalyzes the dephosphorylation of CDC2, which in turn 
activates the cyclin B1/CDC2 complexes at the Tyr 15 site (34, 35). To further address the 
induction of G2/M phase arrest by NCTD in RCC cells, the expression levels of P21, cyclin 
B1, pCDC2, CDC2, pCDC25C, and CDC25C were monitored using western blot analyses. 
The results depicted in Fig. 2b indicate that NCTD treatment induces a concentration- 
- dependent decrease in cyclin B1 and pCDC25C expressions, whereas it increases the levels 
of P21 and pCDC2. Such alternations in protein expressions deactivate the cyclin B1/CDC2 
complexes, thereby blocking the G2/M phase progression. Moreover, defects in G2/M 
checkpoint arrests may allow damaged cells to enter mitosis and undergo apoptosis, an 
active form of cell death in response to toxicants.
Apoptosis is associated with the release of cytochrome c and the increase in cell per-
meability. It may be instigated by the caspase family protein cleavage of PARP (36). As 
shown in Fig. 3a, NCTD treatment causes a significant dose-dependent increase in total 
apoptosis. Meanwhile, western blot results indicate that an increase in NCTD concentra-
tion leads to decreased pro-caspase-3/9 levels while increasing the levels of active cas-
pase-3/9 and cleaved-PARP (Fig. 3b).
The mechanism of NCTD-induced cell apoptosis was further investigated by assess-
ing the role of ERK, JNK and p38, three major members of MAPKs that can be activated by 
upstream dual-specificity kinases. The activation of the ERK cascade is primarily involved 
in cell transformation, differentiation and survival, whereas JNK and p38 cascades are 
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activated in response to physiologic, osmotic or genotoxic stress, endotoxins, pro-inflam-
matory cytokines, and UV exposure (4, 37). Han et al. report that activation of the JNK/c-
Jun pathway by NCTD could accelerate mitochondrial cytochrome c release into the cyto-
plasm and reduce Bcl-2 and Mcl-1 expression levels, leading to caspase activation (38). 
Chen et al. show that NCTD-induced apoptosis was accompanied by elevated phosphory-
lated ERK and JNK levels and activity; however, it did not have any appreciable effect on 
p38 MAPK (39). Similar results were observed in this study, wherein we found that NCTD-
Fig. 3. NCTD induced cell apoptosis in ACHN cells. After cells were treated with 0, 10, 100, and 200 
μmol L–1 NCTD for 24 h, AnnexinV/PI and Western blot were used to detect: a) apoptosis and b) its 
related proteins. *p < 0.05, **p < 0.01, ***p < 0.001 vs. control group.
Fig. 4. NCTD induced the activation of ERK and JNK. Cells treated with 0, 10, 100, and 200 μmol L–1 
NCTD for 24 h were subjected to Western blot assay.
a)
b)
         a)                                                                 b)
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treated RCC cells exhibit increased p-ERK and p-JNK levels, whereas those of p-p38 and 
p38 remain unchanged. The results indicate that NCTD activates JNK and ERK, but not 
p38, MAPK proteins in ACHN cells, in vitro (Fig. 4). Moreover, we show that the p38 in-
hibitor (SB203580) fails to attenuate the inhibitory effect induced by NCTD (data not 
shown), indicating that p38MAPK is not responsible for NCTD-inhibited cell viability.
To further understand the connection between JNK and ERK signaling pathways and 
NCTD-induced G2 phase arrest and apoptosis, the involvement of the two pathways was 
tested using their specific inhibitors of SP600125 and SCH772984. As shown in Fig. 5a,b, 
the proportion of G2/M phase cells in SP600125 pretreated NCTD group was significantly 
Fig. 5. SP600125 attenuate NCTD-induced G2/M arrest and apoptosis. RCC cell lines were pretreated 
with 5 μmol L–1 SP600125 before being exposed to NTCD. a) Cell cycle distribution and b) apoptotic 
cells were detected through PI staining and Annexin V/PI, respectively. c) Related proteins were 
detected by Western blot. *p < 0.05, **p < 0.01, ***p < 0.001 vs. control group.
a)                                                                          b)
c)
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reduced compared with NCTD treated alone (p < 0.05), implying that NCTD-induced 
G2/M arrest could be partially abolished by SP600125. Annexin V/PI results showed that 
SP600125 could partially reverse NCTD-induced apoptosis (Fig. 5b). In addition, NCTD-
induced alternations in the expression levels of cyclinB1, pCDC2, pCDC25C, active cas-
pase-3/9 and cleaved PARP were restored by SP600125 pretreatment (Fig. 5c,d). Similarly, 
pretreatment of ACHN cells with SCH772984 also partially diminished the NCTD-induced 
increase of G2/M cells and apoptosis (Fig. 6). These results clearly implied that the activa-
Fig. 6. SCH772984 attenuate NCTD-induced G2/M arrest and apoptosis. RCC cell lines were pre-
treated with 1 μmol L–1 SCH772984 before being exposed to NTCD. a) Cell cycle distribution and b) 
apoptotic cells were detected through PI staining and Annexin V/PI, respectively. c) Related proteins 
were detected by Western blot. *p < 0.05, **p < 0.01, ***p < 0.001 vs. control group 9.
a)                                                                          b)
c)
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tion of ERK and JNK signaling pathways were involved in NCTD-induced G2/M cell cycle 
arrest and apoptosis. Mechanistically, NCTD had induced RCC cells apoptosis and G2/M 
arrest through triggering modulations of proteins related to cell cycle and DNA damage 
(Fig. 7).
CONCLUSIONS
In summary, the present study shows that the mechanism of NCTD antitumor activ-
ity in ACHN cells is mediated by the ERK and JNK signaling pathways that are involved 
in G2/M cell cycle arrest and apoptosis. The results presented confirm the antitumor po-
tential of NCTD for RCC.
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